New hope for lung cancer patients with scarred lungs: precision radiation trial underway

NCT ID NCT03485378

Ongoing Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase II trial tests a precise type of radiation called SABR in 39 people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. Participants are divided into groups based on the severity of their lung disease, and the study tracks survival, tumor control, and cough severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative radiotherapy (SABR)
What this could lead to: If successful, this could show that precise radiation is a safe and effective option for lung cancer patients who also have interstitial lung disease, offering a treatment path where surgery is not possible.
What could go wrong: This is a small, early-phase study with only 39 participants, so results may not apply to everyone. Radiation can cause lung inflammation or scarring, especially in patients with existing lung disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Alberta Health Services, Cross Cancer Institude

Edmonton, Alberta, T6G 1Z2, Canada
CHUM Université de Montréal

Montreal, Quebec, H2X 0A9, Canada
Edinburgh Cancer Centre, Western General Hospital

Edinburgh, EH4 2XU, United Kingdom
London Regional Cancer Program of the Lawson Health Research Institute

London, Ontario, N6A 4L6, Canada
Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada
UHN Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.